MRI for MMN and CIDP - Towards improved diagnostic accuracy and dissection of pathophysiology.

MRI for MMN and CIDP - Towards improved diagnostic accuracy and dissection of pathophysiology. - MIMIC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48985

Enrollment

190

Registered

2018-07-11

Start date

2018-09-05

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immuun-mediated/treatable polyneuropathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age 18- 80 years. 2. Patients: confirmed diagnosis of CIDP or MMN, as defined by relevant diagnostic consensus criteria. 3. Disease controls: established diagnosis of relevant clinical mimic to diagnosis CIDP and MMN (CMT, lower motor neuron syndromes and axonal neuropathies). 4. Healthy volunteers: no previous diagnosis, sign/symptoms consistent with neuropathy

Exclusion criteria

Exclusion criteria: 1. age 80 years, 2. physically unable to undergo MRI or HRUS of the peripheral nervous system

Design outcomes

Primary

Measure	Time frame
The main study parameters for objective 1, are: 1. (Semi-)quantitative rating of MRI-imaging of brachial plexus. 2. Cross-sectional area (CSA) on HRUS imaging (CSA measurements of median nerves and brachial plexus). These parameters will be used to select those with highest diagnostic yield as endpoint. The main parameters for objective 2, are: 1. MRI-DTI values (radial, axial and mean diffusivity (RD, AD and MD), fractional anisotropy (FA)). The will be used to determine the distribution of parameters and nerve size that may be useful in the future for patients with CIDP and MMN.	—

Measure

Time frame

The main study parameters for objective 1, are: 1. (Semi-)quantitative rating of MRI-imaging of brachial plexus. 2. Cross-sectional area (CSA) on HRUS imaging (CSA measurements of median nerves and brachial plexus). These parameters will be used to select those with highest diagnostic yield as endpoint. The main parameters for objective 2, are: 1. MRI-DTI values (radial, axial and mean diffusivity (RD, AD and MD), fractional anisotropy (FA)). The will be used to determine the distribution of parameters and nerve size that may be useful in the future for patients with CIDP and MMN.

—

Countries

Netherlands

Outcome results